Jason Henry, MD
Internal Medicine · Denver, CONPI 1396163010
Payments from drug & device makers
Across 1,299 payments — averaging $5629.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche TCRC, Inc.$1.3M
- Seagen Inc.$1.2M
- Mirati Therapeutics, Inc.$1.1M
- Incyte Corporation$877K
- E.r. Squibb & Sons, L.L.C.$688K
- Takeda Pharmaceuticals U.S.A., Inc.$627K
- plus $1.5M from 28 others
Across 2 payments — averaging $590.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$940
- Amgen$241
What the payments were for
- Consulting fees$8,18280%
- Travel & lodging$1,09311%
- Food & beverage$9559%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche TCRC, Inc. | 14 | $1,332,164 |
| Seagen Inc. | 178 | $1,166,462 |
| Mirati Therapeutics, Inc. | 316 | $1,095,398 |
| Incyte Corporation | 346 | $876,701 |
| E.r. Squibb & Sons, L.L.C. | 9 | $687,592 |
| Takeda Pharmaceuticals U.S.A., Inc. | 119 | $627,038 |
| Pfizer | 104 | $482,076 |
| Merck | 6 | $246,586 |
| Eli Lilly | 1 | $201,471 |
| Amgen | 4 | $174,770 |
| AbbVie | 60 | $117,101 |
| Boehringer Ingelheim | 34 | $106,509 |
| Astellas Pharma Inc | 39 | $100,445 |
| GSK | 23 | $53,674 |
| Genentech, Inc. | 16 | $35,717 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $7,139 |
| Boehringer Ingelheim International GmbH | 5 | $782 |
| Tersera Therapeutics LLC | 3 | $107 |
| Johnson & Johnson | 2 | $45 |
| Caris MPI, Inc. | 2 | $44 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Array Biopharma Inc | 2 | $38 |
| Histosonics, Inc. | 1 | $37 |
| Delcath Systems | 1 | $36 |
| Astellas Pharma US Inc | 1 | $34 |
| Genmab U.S., Inc. | 1 | $34 |
| Genentech USA, Inc. | 1 | $32 |
| Immunocore Limited | 1 | $31 |
| Tempus AI, Inc | 1 | $23 |
| AstraZeneca | 1 | $23 |
| Foundation Medicine, Inc. | 1 | $21 |
| EMD Serono, Inc. | 1 | $20 |
| Abbott | 1 | $18 |
| Eisai Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FRUZAQLA$7,693
How this compares
$7,312,225 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other internal medicine in Denver
- Thomas StarkeyDenver$391K
- Matthew KoslowDenver$182K
- Keith HruskaDenver$167K
- Kenneth OleszekDenver$60K
- Robert KeithDenver$49K
- Elena AnisimovaDenver$36K
- Chase BlackfordDenver$30K
- Samuel BrownDenver$18K
- Katherine TsaiDenver$15K
- Saurabh MangalikDenver$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.